nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.07.2005 | Original Paper

Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma

verfasst von: Ken Nakatani, Takeshi Wada, Megumi Nakamura, Katsuhiro Uzawa, Hideki Tanzawa, Shigeyuki Fujita

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose: Cisplatin (CDDP) is widely used for chemotherapy of oral squamous cell carcinoma (OSCC). However, the mechanism of resistance to CDDP is unclear. Recently, caveolin-1 was identified as being associated with both metastasis and multidrug resistance. In the present study, we showed that caveolin-1 expression is significantly related to chemosensitivity in OSCC. Methods: We established a CDDP-resistant cell line, H-1R, from the parental OSCC cell line, H-1. Caveolin-1 expression was determined by reverse transcriptase–polymerase chain reaction (RT-PCR) in both cell lines. We analyzed expression of caveolin-1 in 30 OSCC biopsy specimens and investigated the relationship between expression of caveolin-1 and patients‘ clinicopathological parameters and chemotherapeutic responses. Results: The 3-(3,4-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay indicated that H-1R has a ten-times greater resistance to CDDP than H-1 has. The level of caveolin-1 expression in H-1R was significantly decreased in comparison with that in H-1 by real-time RT-PCR analysis. Positive caveolin-1 immunostaining correlated positively with a complete response (16/20, 80.0%). However, negative immunostaining was found in 6/7 (85.7%) cases with no response. Positive immunohistochemical staining of caveolin-1 correlated positively with chemosensitivity to CDDP-based combination chemotherapy (P=0.02). Conclusions: These results suggest that overexpression of the caveolin-1 gene may provide novel diagnostic markers associated with CDDP sensitivity in OSCC.

Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, Eng C (2003) Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63:2864–2871

Anderson RGW (1998) The caveolae membrane system. Annu Rev Biochem 67:199–225

Belanger MM, Roussel E, Couet J (2003) Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. AntiCancer Drugs 14:281–287

Cammano J, Ruggeri B, Momiki S, Sickler A, Zhang SY, Klein-Szanto AJ (1991) Detection of p53 in primary lung tumors and nonsmall cell lung carcinoma cell lines. Am J Pathol 139:839–845

Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated calorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942

Cognetti F, Pinnaro P, Carlini P, Ruggeri EM, Ambesi Impiombato F, Del Vecchio MR, Giannarelli D, Perrino A (1988) Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer. Cancer 62:251–261

Decker DA, Drelichman A, Jacobs J, Hoschner J, Kinzie J, Loh JJ, Weaver A, Al-Sarraf M (1983) Adjuvant chemotherapy with cis-diaminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 51:1353–1355

Ensley J, Crissman J, Kish J, Jacobs J, Weaver A, Kinzie J, Cummings G, Al-Sarraf M (1986) The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer 57:711–717

Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL, Posner MR, Norris CM Jr, Tuttle SA, Schoenfeld DA (1987) An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous cell carcinoma of the head and neck. J Clin Oncol 5:10–20

Fielding CJ, Bist A, Fielding PE (2000) Intracellular cholesterol transport in synchronized human skin fibroblasts. FEBS Lett 466:219–224

Fine SW, Lisanti MP, Galbianti F, Li M (2001) Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 115:719–724

Futscher BW, Abbaszadegan MR, Domann F, Dalton WS (1994) Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol 47:1601–1606

Han SE, Park KH, Lee G, Huh YJ, Min BM (2004) Mutation and aberrant expression of caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int J Oncol 24:435–440

Hermanek P, Sobin LH (1992) TNM classification of malignant tumors, 4th edn, 2nd revision. International Union Against Cancer, Springer, Berlin Heidelberg New York

Hill BT, Price LA (1990) The role of adjuvant chemotherapy in the treatment of advanced head and neck cancer. Acta Oncol 29:695–703

Hino M, Doihara H, Kobayashi K, Aoe M, Shimizu N (2003) Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today 33:486–490

Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H (2002) Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94:929–933

Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC (1996) Accumulation of glucosylceramides in multidrug resistant cancer cells. J Biol Chem 271:19530–19536

Lavie Y, Fiucci G, Liscovitch M (1998) Up-regulation of caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273:32380–32383

Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE (1998) Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16:1391–1397

Liu J, Lee P, Galbiati F, Kitsis RN, Lisanti MP (2001) Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol Cell Physiol 280:C823–C835

Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

Moriya T, Seki N, Shimada K, Kato K, Yakushiji T, Nimura Y, Uzawa K, Takiguchi M, Tanzawa H (2003) In-house cDNA microarray analysis of gene expression profiles involved in SCC cell lines. Int J Mol Med 12:429–435

Nakamura M, Nakatani K, Uzawa K, Seki N, Fujita S, Tanzawa H (2004) Establishment and gene analysis of a cisplatin-resistant cell line, H-1R, derived from oral squamous cell carcinoma. Oncology Reports (in press)

Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC (1998) Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4:1062–1064

Okamoto T, Schlegel A, Scherer PE, Lisanti MP (1998) Caveolins, a family of scaffolding proteins for organizing “pre-assembled signaling complexes” at the plasma membrane. J Biol Chem 273:5419–5422

Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK (2001) Caveolin-1 expression is associated with high-grade bladder cancer. Urology 58:811–814

Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG (1992) Caveolin, a protein component of caveolae membrane coats. Cell 68:673–682

Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJ, Pemberton P (1994) RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb Symp Quant Biol 59:537–546

Shimosato Y, Oboshi S (1971) Histological evaluation of effects of radiotherapy and chemotherapy for carcinoma. Jpn J Clin Oncol 1:19–35

Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, Lisanti MP (1999) Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19:7289–7304

Sobin LH, Wittekind CH (eds) (1997) International Union Against Cancer TNM classification of malignant tumours, 5th edn. Wiley, New York

Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H (2002) Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87:1140–1144

Timme TL, Goltsv A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC (2000) Caveolin-1 is regulated by c-myc and suppresses c-myc induced apoptosis. Oncogene 19:3256–3265

Urba SG, Forastiere AA (1989) Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncology 3:79–88

Vogl SE, Lerner H, Kaplan BH, Coughlin C, McCormick B, Camacho F, Cinberg J (1982) Failure of effective initial chemotherapy to modify the course stage IV (M0) squamous cancer of the head and neck. Cancer 50:840–844

Wada T, Harada M, Morita N, Oomata T, Koizumi T, Kawashima T, Sakamoto T (1995) Chemotherapy administered using two-route infusion of cisplatin and sodium thiosulfate and intravenous infusion of vinblastine and peplomycin in patients with oral cancer. Clin Ther 17:280–289

Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, Sers C (2001) Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 159:1635–1643

Yang CPH, Galbiati F, Volonte D, Horwits SB, Lisanti MP (1998a) Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 439:368–372

Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC (1998b) Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4:1873–1880

Yang G, Truong LD, Wheeler TM, Thompson TC (1999) Caveolin-1 expression in clinically confirmed human prostate cancer: a novel prognostic marker. Cancer Res 59:5719–5723

Titel: Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma
verfasst von: Ken Nakatani
Takeshi Wada
Megumi Nakamura
Katsuhiro Uzawa
Hideki Tanzawa
Shigeyuki Fujita
Publikationsdatum: 01.07.2005
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2005
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-004-0662-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma

Abstract

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2005

Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization

Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response

Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma

The biological effect of pentoxifylline on the survival of human head and neck cancer cells treated with continuous low and high dose-rate irradiation

Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women

The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie